CEO — Brian Carrico: The filing discloses a stock option exchange and new RSU grants, which are compensatory arrangements rather than a change in management or officer departure.

Other Events On July 9, 2026, the Board of Directors of Neuraxis, Inc. (the “ Company ”) authorized and the Company declared a stock dividend on the Company’s Series B Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”) for the second quarter of 2026 (the “ Second Quarter Dividend ”). The Second Quarter Dividend will be paid in the form of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The number of shares of Common Stock to b…

Other Events. As previously disclosed, on August 29, 2025, the Company entered into an At The Market Offering Agreement (the “Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (the “Common Stock”), having an aggregate offering price of up to $6,270,000, through the Sales Agent as its sales agent. Pursuant to the Agreement, sales of the Common Stoc…

Results of Operations and Financial Condition On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025. On a preliminary unaudited basis, the Comp…

Other Events. FDA 510(k) Clearance NeurAxis, Inc. (“NeurAxis” or the “Company”) today announced that it has received U.S. Food and Drug Administration (the “FDA”) 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (“PENFS”) technology for the treatment of functional abdominal pain (“FAP”) associated with functional dyspepsia (“FD”), and FD related nausea symptoms, in patients aged 8 years and older. The FDA reviewed the clinical literature supporting the use…

Results of Operations and Financial Condition On October 23, 2025, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales to be approximately $0.8 million, its gross profits to be approximately $0.7 million, and its operating loss to be approximately $2.1 million, for the three months…

Entry into a Material Definitive Agreement. On August 29, 2025, Neuraxis, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with Craig-Hallum Capital Group LLC (the “ Sales Agent ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (the “ Common Stock ”), having an aggregate offering price of up to $3,300,000, through the Sales Agent as its sales agent. Pursuant to the Agr…

Termination of a Material Definitive Agreement. The information contained in

Entry into a Material Definitive Agreement. As previously disclosed, on April 9, 2020, Neuraxis, Inc. (the “ Company ”) entered into a license and collaboration agreement (the “ License and Collaboration Agreement ”) with Masimo Corporation (“ Masimo ”). Under the License and Collaboration Agreement, the Company granted Masimo an exclusive, fully paid-up, royalty-free license to certain specifically identified patents and trademarks in a limited field of use, in connection with the NSS-2 Brid…

The filing describes the adoption of a new employee stock purchase plan, which is not related to any management change.

Entry Into a Material Definitive Agreement. On May 20, 2025, Neuraxis, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 1,538,461 shares (the “ Shares ”) of common stock of the Company, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $3.25 per share of Common Stock (the “ Offering ”). The Shares were offered by the Comp…

Entry Into a Material Definitive Agreement. As previously disclosed, from February 2019 through July 2022, Ritu Bhambhani, M.D., Sudhir Rao, M.D., Ritu Bhambhani, LLC d/b/a Complete Care of Maryland; Box Hill Surgery Center, LLC, Pain and Spine Specialists of Maryland, LLC, SimCare ASC, LLC (together, the “ Releasing Parties ”) initiated lawsuits against the Company. As previously disclosed, the Company and Releasing Parties reached a tentative settlement on April 25, 2025. On May 15, 2025, t…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in

Results of Operations and Financial Condition On January 8, 2025, Neuraxis, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its preliminary unaudited information about the Company’s estimated revenues for the three and twelve months ended December 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The preliminary financial information contained in the Press Release is unaudited and preliminary and does not p…

Director — Dr. Gil Aharon: Dr. Gil Aharon was appointed to the Board of Directors as a result of an investment transaction.

Material Modification to Rights of Security Holders. To the extent required by

Entry into a Material Definitive Agreement. On November 9, 2024, Neuraxis, Inc. (the “ Company ”) entered into securities purchase agreements (the “ SPAs ”) with three related investors (the “ Investors ”) for the issuance and purchase of a total of 2,100,840 shares of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”) for an aggregate purchase price of approximately $5 million (the “ Transaction ”). To facilitate the Transaction,…

Unregistered Sales of Equity Securities. The disclosure regarding the issuance of the Series B Preferred Stock shares required by this

Results of Operations and Financial Condition On November 12, 2024 Neuraxis, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information contained in Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…

Unregistered Sales of Equity Securities. The disclosure regarding the SPAs required by this

Entry into a Material Definitive Agreement. Amendment to Flagstaff SPA As previously disclosed, on November 9, 2023, Neuraxis, Inc. (the “Company”) entered into a securities purchase agreement (the “Flagstaff SPA”), with Flagstaff International, LLC (“Flagstaff International”) for the issuance and purchase of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at price per share of $2.38. The aggregate purchase price of $3 million w…

Unregistered Sales of Equity Securities As previously disclosed, on November 9, 2023, Neuraxis, Inc. (the “Company”) entered into a securities purchase agreement, as amended, with Flagstaff International, LLC (“Flagstaff International”) for the issuance and purchase of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at a price per share of $2.38. As previously disclosed, the aggregate purchase price, as amended on March 22, 2024…

Results of Operations and Financial Condition On August 9, Neuraxis, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information contained in Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the lia…

The filing describes the grant of stock awards to non-employee directors as compensation for their services.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement The disclosure regarding the Notes required by this